Kinetics of avibactam inhibition against Class A, C, and D β-lactamases.

J Biol Chem

From the Infection Innovative Medicines Unit and the Discovery Sciences Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts 02451.

Published: September 2013

Avibactam is a non-β-lactam β-lactamase inhibitor with a spectrum of activity that includes β-lactamase enzymes of classes A, C, and selected D examples. In this work acylation and deacylation rates were measured against the clinically important enzymes CTX-M-15, KPC-2, Enterobacter cloacae AmpC, Pseudomonas aeruginosa AmpC, OXA-10, and OXA-48. The efficiency of acylation (k2/Ki) varied across the enzyme spectrum, from 1.1 × 10(1) m(-1)s(-1) for OXA-10 to 1.0 × 10(5) for CTX-M-15. Inhibition of OXA-10 was shown to follow the covalent reversible mechanism, and the acylated OXA-10 displayed the longest residence time for deacylation, with a half-life of greater than 5 days. Across multiple enzymes, acyl enzyme stability was assessed by mass spectrometry. These inhibited enzyme forms were stable to rearrangement or hydrolysis, with the exception of KPC-2. KPC-2 displayed a slow hydrolytic route that involved fragmentation of the acyl-avibactam complex. The identity of released degradation products was investigated, and a possible mechanism for the slow deacylation from KPC-2 is proposed.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784710PMC
http://dx.doi.org/10.1074/jbc.M113.485979DOI Listing

Publication Analysis

Top Keywords

kinetics avibactam
4
avibactam inhibition
4
inhibition class
4
class β-lactamases
4
β-lactamases avibactam
4
avibactam non-β-lactam
4
non-β-lactam β-lactamase
4
β-lactamase inhibitor
4
inhibitor spectrum
4
spectrum activity
4

Similar Publications

Carbapenemase OXA-48 and its variants pose a serious threat to the development of effective treatments for bacterial infections. OXA-48-producing Enterobacterales are the most prevalent carbapenemase-producing bacteria in large parts of the world. Although these bacteria exhibit low-level carbapenem resistance , the infections they cause are challenging to treat with conventional therapies, owing to their spread and complex detection in clinical settings.

View Article and Find Full Text PDF

() presents significant clinical challenges. This study evaluated the synergistic effects of a β-lactam and β-lactamase inhibitor combination against and explored the underlying mechanisms. Synergy was assessed through MIC tests and time-kill studies, and binding affinities of nine β-lactams and BLIs to eight target receptors (L,D-transpeptidases [LDT] 1-5, D,D-carboxypeptidase, penicillin-binding protein [PBP] B, and PBP-lipo) were assessed using mass spectrometry and kinetic studies.

View Article and Find Full Text PDF

Objectives: In this study, we discovered bla in ceftazidime-avibactam resistant clinical isolates of K. pneumoniae from a patient with multiple comorbidities and investigated the resistance & transfer mechanism of bla.

Methods: K.

View Article and Find Full Text PDF

KSA-1, a naturally occurring Ambler class A extended spectrum β-lactamase from the enterobacterial species Kosakonia sacchari.

J Glob Antimicrob Resist

December 2024

Medical and Molecular Microbiology Unit, University of Fribourg, Fribourg, Switzerland; Swiss National Center for Emerging Antibiotic Resistance, University of Fribourg, Fribourg, Switzerland. Electronic address:

Background: Several bacterial species belonging to the Gammaproteobacteria possess intrinsic class A β-lactamase genes that may represent a source of further dissemination and acquisition to other Gram-negative species. Here we characterised KSA-1 class A β-lactamase, the gene of which was identified within the chromosome of an environmental Enterobacterales species, namely Kosakonia sacchari, which was also recently identified as the progenitor of an MCR-like colistin-resistance determinant.

Methods: In silico analysis using the GenBank database identified a class A β-lactamase gene within the chromosome of K.

View Article and Find Full Text PDF

Characterization of a KPC-84 harboring Klebsiella pneumoniae ST11 clinical isolate with ceftazidime-avibactam resistance.

Eur J Clin Microbiol Infect Dis

October 2024

Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China.

A novel KPC variant, KPC-84, identified in a Klebsiella pneumoniae isolate from China, exhibits a threonine (T) to proline (P) amino acid substitution at Ambler position 243(T243P), altering from the KPC-2 sequence. Cloning and expression of bla in Escherichia coli, with subsequent MIC assessments, revealed increased resistance to ceftazidime-avibactam and significantly reduced carbapenemase activity compared to KPC-2. Kinetic measurements showed that KPC-84 exhibited sligthly higher hydrolysis of ceftazidime and reduced affinity for avibactam compared to KPC-2.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!